Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty pharmaceutical firm Cumberland Pharmaceuticals (CPIX) has acquired Astellas Pharma's patented, prescription brand Vaprisol, which is indicated to raise serum sodium levels in hospitalized patients with hyponatremia.
Subscribe to our email newsletter
Vaprisol was developed and registered by Astellas and was commercially launched in 2006 and it is one of two branded prescription products indicated for the treatment of hyponatremia.
Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal and its can be related with several critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.
As part of the deal, Cumberland will be responsible for manufacturing, marketing, distributing and promoting Vaprisol across the US through its hospital sales force, which also features its Caldolor and Acetadote brands.
Cumberland Pharmaceuticals chief executive officer AJ Kazimi said the company believes Vaprisol is an excellent strategic fit with its focus on hospital acute care.
"Our immediate plan for Vaprisol is to ensure a smooth transition of the product supply and medical support to current users of the brand," Kazimi said.
"We will then launch our hospital promotion support and are very optimistic about the opportunity that Vaprisol will offer Cumberland."